SerpApi.Org SerpApi.Org

Search Everything in One Place

Explore the web, images, videos, news, and more – all in one place.

🌐 Web 🖼️ Images 🎥 Videos 📰 News 🛍️ Shopping
Finance

These analysts boost their forecasts on General Motors after better-than-expected Q2 results

· · 1 min read
Marion - Circa October 2021: General Motors Logo and Signage at the Metal Fabricating Division. GM opened this plant in 1956.
Marion - Circa October 2021: General Motors Logo and Signage at the Metal Fabricating Division. GM opened this plant in 1956.

General Motors GM on Tuesday reported better-than-expected second-quarter financial results and raised its FY26 adjusted EPS guidance with its midpoint above estimates. General Motors reported quarterly earnings of $3.57 per share which beat the analyst consensus estimate of $3.20 per share. The company reported quarterly sales of $48.026 billion which beat the analyst consensus estimate of $47.011 billion. GM raised its 2026 adjusted EPS...

General Motors GM on Tuesday reported better-than-expected second-quarter financial results and raised its FY26 adjusted EPS guidance with its midpoint above estimates.

General Motors reported quarterly earnings of $3.57 per share which beat the analyst consensus estimate of $3.20 per share. The company reported quarterly sales of $48.026 billion which beat the analyst consensus estimate of $47.011 billion.

GM raised its 2026 adjusted EPS guidance to $12-$14 from its previous range of $11.50-$13.50. The new outlook compares with the analyst consensus estimate of $12.76. The automaker also increased its adjusted EBIT guidance to $14 billion-$16 billion from $13.5 billion-$15.5 billion.

However, GM lowered its GAAP diluted EPS forecast to $8.98-$10.98 from $10.62-$12.62. Analysts had expected $10.80.

General Motors shares fell 2.5% to trade at $168.72 on Wednesday.

These analysts made changes to their price targets on General Motors following earnings announcement.

  • Barclays analyst Dan Levy maintained the stock with an Overweight rating and raised the price target from $105 to $110.
  • JP Morgan analyst Rajat Gupta maintained the stock with an Overweight rating and raised the price target from $110 to $120.
  • RBC Capital analyst Tom Narayan maintained the stock with an Outperform rating and raised the price target from $94 to $100.

Considering buying GM stock? Here’s what analysts think:

These Analysts Boost Their Forecasts On General Motors After Better-Than-Expected Q2 Results

Photo via Shutterstock

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

This article These Analysts Boost Their Forecasts On General Motors After Better-Than-Expected Q2 Results originally appeared on Benzinga.com.

Tags: Money Stocks Business
Read full story on Benzinga

Related News

More stories you might be interested in.

Chubb slips on earnings day, but analysts bet on its global moat
Benzinga·1 hour ago

Chubb slips on earnings day, but analysts bet on its global moat

Shares of Chubb Limited CB tanked in early trading on Wednesday, after the company reported in-line second-quarter results. Here are some key analyst takeaways: Cantor Fitzgerald analyst Ryan Tunis maintained a Neutral rating and price target of $337. Citizens JMP Securities analyst Matthew Carletti reiterated a Market Outperform rating and price target of $400. Check out other analyst stock ratings. Cantor Fitzgerald: Chubb reported core...
CrowdStrike partners with Cerebras to boost AI cybersecurity
Benzinga·1 hour ago

CrowdStrike partners with Cerebras to boost AI cybersecurity

CrowdStrike Holdings Inc. CRWD and Cerebras Systems Inc. CBRS announced a strategic partnership Wednesday to strengthen artificial intelligence-powered cybersecurity. Under the agreement, CrowdStrike will use Cerebras’ AI inference technology to power Falcon AI Detection and Response (AIDR). In return, Cerebras will standardize on the CrowdStrike Falcon platform to secure its own business. The companies said the partnership combines high-speed...
FDA approves Johnson & Johnson table-integrated OTTAVA robotic surgery system
Benzinga·1 hour ago

FDA approves Johnson & Johnson table-integrated OTTAVA robotic surgery system

The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson’s JNJ OTTAVA Robotic Surgical System, marking the regulatory clearance of the world’s first table-integrated soft tissue robotic platform. The marketing clearance encompasses multiple general surgery procedures. The medical technology giant will initiate a commercial rollout with select U.S. facilities, prioritizing initial customer success...
SMCX pops 50% as Super Micro shocks Wall Street with AI margin windfall
Benzinga·1 hour ago

SMCX pops 50% as Super Micro shocks Wall Street with AI margin windfall

The Defiance Daily Target 2X Long SMCI ETF SMCX surged nearly 50% Wednesday, delivering roughly twice the gains of its underlying stock as traders piled into Super Micro Computer Inc. SMCI following a blockbuster preliminary fourth-quarter update. While SMCI jumped 26% on stronger-than-expected margins and a record AI order pipeline, SMCX emerged as one of the session’s top-performing leveraged ETFs, highlighting the growing appeal of...
Top